Clinical trials: Hair Thinning
Alopecia Areata, Alopecia Totalis
Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata
This study is a randomized, double-blind, placebo-controlled, multi-center, dose-ranging study to characterize the efficacy and safety of BNZ-1 administered by slow IV push weekly for 3 months to adults diagnosed with moderate to…
- Conditions
- Alopecia Areata, Alopecia Totalis, Alopecia Universalis
- Trial name
- NCT03532958
- Testing
- BNZ-1, Normal saline
- Sponsor
- Equillium
Alopecia, Male Pattern Hair Loss
To Evaluate Efficacy, Safety, and Tolerability of KX-826 in Male Subjects With Androgenetic Alopecia
The study is a randomized, double-blind, placebo-controlled, parallel group, phase 2 study to evaluate the efficacy, safety and tolerability of KX-826 in male subjects with androgenetic alopecia.
- Trial name
- NCT05218642
- Testing
- KX- 826 dosed at 2.5mg, KX-826 dosed at 5mg
- Where
- 10 sites in United States
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
Androgenetic Alopecia (AGA)
To Evaluate Efficacy and Safety of TopicalKX-826 Solution in Chinese Male Patients With Androgenetic Alopecia
This study is a multicenter, randomized, double-blind, vehicle controlled, adaptive design phase 2/3 study to evaluate the efficacy and safety of topical KX-826 solution in Chinese male patients with androgenetic alopecia (AGA).
- Trial name
- NCT06622824
- Testing
- KX-826 0.5% BID, KX-826 1.0% BID
- Where
- China
- Volunteers
- 756 people
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
Alopecia Areata, Alopecia Universalis
ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)
This is an open label study of ATI-502 Topical Solution for the treatment of AA, AU, and AT with the following goals: To assess the safety, tolerability, and efficacy of ATI-502 Topical Solution in subjects with AA, AU or AT…
- Conditions
- Alopecia Areata, Alopecia Universalis, Alopecia Totalis
- Trial name
- NCT03759340
- Testing
- ATI 502 0.46% Topical Solution
- Where
- 20 sites in United States
- Volunteers
- 56 people
- Sponsor
- Aclaris Therapeutics, Inc.
Actinic Keratosis
Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis
To identify the Maximum Tolerated Dose levels of ingenol mebutate gel after once daily treatment for 2 or 3 consecutive days and to evaluate efficacy of ingenol mebutate gel in different doses after once daily treatment for 2 or…
- Trial name
- NCT01820260
- Testing
- Ingenol mebutate gel
- Where
- United States
- Volunteers
- 395 people
- Sponsor
- LEO Pharma
Male Pattern of Hair Loss, Androgenic Alopecia
Minoxidil 5% / Botanical Hair Regimen in Men With Thinning Hair and Male Pattern Hair Loss/Androgenic Alopecia
The purpose of this study is to characterize the effect of Minoxidil 5% Foam and Botanical Hair Solution Regimen in men with thinning hair and male pattern hair loss/androgenic alopecia (Norwood III \& IV).
- Trial name
- NCT02460289
- Testing
- Treatment: Minoxidil 5% / Botanical Hair Solution for Men
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Galderma R&D
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002012)
To evaluate the ability of injections of Ji Gami(TM) and Ji Gami(TM) DO to induce hair growth in male and female subjects with hair loss
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451047
- Testing
- Autologous cultured dermal and epidermal cells
- Where
- 7 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Alopecia
Safety and Preliminary Efficacy Study of MTS-01 for the Prevention of Alopecia Induced by WHole Brain Radiotherapy
The purpose of this study is to determine if MTS-01 is effective in preventing radiotherapy-induced hair loss in patients receiving whole brain radiotherapy
- Trial name
- NCT00713154
- Testing
- MTS-01
- Volunteers
- 16 people
- Sponsor
- Mitos Pharmaceuticals
Thin Hair, Hair Loss
Study to Evaluate Xtresse Serum in Individuals With Thinning Hair
The goal of this study is to determine how safe and effective it is to improve hair growth by applying a serum daily on the scalp of men and women with thinning hair. The main aims of this trial are: 1.
- Conditions
- Thin Hair, Hair Loss, Alopecia, Thinning Hair
- Trial name
- NCT07228156
- Testing
- Xtresse Serum
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Restore Biologics Holdings, Inc. dba Xtressé
Alopecia
Bioequivalence Study of Dutasteride Five 0.1 mg and One 0.5 mg Soft Gelatin Capsules in Healthy Male Volunteers
The aim of this study is to determine the bioequivalence of 5 x 0.1 milligram (mg) capsules compared to 1 x 0.5 mg capsule of dutasteride in healthy male subjects.
- Trial name
- NCT01929330
- Testing
- GI198745 0.1 mg, GI198745 0.5 mg
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy, Active Non-segmental Vitiligo
Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration
A multicenter clinical study to evaluate the safety, PK characteristics, immunogenicity characteristics, and PD characteristics of IBI3013 in healthy trial participants and active non-segmental vitiligo trial participants and…
- Conditions
- Healthy, Active Non-segmental Vitiligo, Severe Alopecia Areata
- Trial name
- NCT07554222
- Testing
- Baricitinib tablets, IBI3013
- Where
- China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Actinic Keratoses
Single-Center Study Evaluating Systemic Exposure and Safety of KX2-391 Ointment 1% on the Face or Balding Scalp in Subjects With Actinic Keratosis
This Phase I study is designed to evaluate the systemic exposure and safety of KX2-391 Ointment in adult subjects when applied to an area of skin containing at least 5 clinically typical, visible, and discrete Actinic Keratosis…
- Trial name
- NCT03575780
- Testing
- KX2-391 Ointment 1%
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Athenex, Inc.
Alopecia Areata
Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata
The purpose of this study is to assess the preliminary efficacy, safety, tolerability, PK, and PD of Daxdilimab in participants with moderate to severe AA, with ≥50% and ≤95% total scalp hair loss as defined by the SALT score at…
- Trial name
- NCT05368103
- Testing
- Daxdilimab
- Where
- 13 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Amgen
Male Pattern Baldness, Female Pattern Baldness
Low Level Light Therapy (LLLT) for Hair Growth
A total of 62 participants will receive red light (660 nm) to the scalp through a specially designed light therapy device integrated into a conventional hat.
- Trial name
- NCT03938948
- Testing
- low-level laser/light therapy
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Awareable Technologies Inc
Gut Dysbiosis, Telogen Effluvium
Gut Microbiota and Trichoscopic Changes in Women With Telogen Effluvium on a Multifactorial Drinkable Nutraceutical: A Retrospective Observational Study
Telogen effluvium (TE) is a common cause of diffuse, non-scarring hair shedding in women. It is often triggered by physiological stress, nutritional deficiencies, illness or hormonal changes.
- Conditions
- Gut Dysbiosis, Telogen Effluvium, Hair Loss
- Trial name
- NCT07869199
- Testing
- Drinkable multifactorial food supplement containing vitamins, minerals, plant extracts, and other bioactive compounds, formulated to support hair growth and scalp health in women.
- Where
- 2 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Olistic Research Labs S.L.
Alopecia, Androgenetic
A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA)
Multi-center, randomized, double-blind, vehicle-controlled, parallel group, multi-dose escalation study of TDM-105795 in male subjects, 18 to 55 years old, with Androgenetic Alopecia (AGA).
- Trial name
- NCT05244980
- Testing
- TDM-105795
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Technoderma Medicines Inc.
COVID-19, SARS-CoV2
Anti-Androgen Treatment for COVID-19
This study is intended to explore the possible protective role of anti-androgens in SARS-CoV-2 infection
- Conditions
- COVID-19, SARS-CoV2, Androgenetic Alopecia, Prostate Cancer
- Trial name
- NCT04446429
- Testing
- Proxalutamide, Standard of Care
- Where
- Brazil
- Volunteers
- 268 people
- Sponsor
- Applied Biology, Inc.
Female Pattern Hair Loss, Female Pattern Hair Loss, Androgenic Alopecia
Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of N1087 in Participants With Female Pattern Hair Loss (MINORA-WOMEN)
This is a Phase 3, prospective, randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical trial designed to evaluate the efficacy and safety of N1087 in women with female pattern hair loss (FPHL).
- Trial name
- MINORA-WOMEN (NCT07303322)
- Testing
- N1087
- Volunteers
- 372 people
- Sponsor
- Eurofarma Laboratorios S.A.
Androgenetic Alopecia, Hair Loss
Treatment of Androgenic Alopecia in Males
The purpose of this study is to evaluate the change in terminal hair count at 16 and 26 weeks compared to baseline measurements.
- Conditions
- Androgenetic Alopecia, Hair Loss, Male Pattern Baldness
- Trial name
- NCT00947219
- Testing
- HairMax LaserComb, Control device
- Where
- 3 sites in United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Lexington International, LLC
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Dermal Cells Into the Balding Scalp of Subjects With Hair Loss
Evaluate the ability of Ji Gami(TM) DO to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451099
- Testing
- Autologous cultured dermal cells
- Where
- 6 sites in United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute